Cyramza (ramucirumab) / Eli Lilly, Innovent Biologics - LARVOL DELTA

FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for taxane-pretreated patients with advanced or metastatic gastroesophageal adenocarcinoma–Final results of the phase III IKFs602/AIO RAMIRIS Study (ESMO 2026) - No abstract available

Clinical • Metastases • P3 data • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

Current and Emerging Targeted Therapy in Advanced Gastroesophageal Adenocarcinoma. (PubMed, Pharmaceuticals (Basel)) - " HER2-directed therapy has progressed from trastuzumab through dual blockade, immunotherapy combinations, next-generation ADCs (notably trastuzumab deruxtecan) and bispecific antibodies such as zanidatamab, which has now overtaken trastuzumab in the first-line setting. CLDN18.2-targeted zolbetuximab has demonstrated survival benefit in biomarker-selected patients, with newer ADCs, BiTEs and the first approved solid-tumour CAR-T therapy (satricabtagene autoleucel) extending this target further. VEGFR2 inhibition with ramucirumab remains a cornerstone in later lines, while novel VEGF/PD-1(L1) bispecifics are under investigation. FGFR2b-targeted bemarituzumab showed early promise that weakened on phase 3 confirmation, and MET/EGFR-directed agents, including savolitinib and amivantamab, require stringent biomarker selection to demonstrate benefit amid tumour heterogeneity. Novel targeted agents, particularly to HER2 and CLDN18.2, have demonstrated survival benefit despite..."

IO biomarker • Journal • Review • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • CLDN18

Impact of prior immune checkpoint inhibitor (ICI) treatments on the clinical outcomes of trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in human epidermal growth factor receptor 2–positive (HER2+) advanced gastric cancer (GC)/ gastroesophageal junction adenocarcinoma (GEJA): exploratory analysis from DESTINY-Gastric04 (DG-04) (ESMO 2026) - No abstract available

Checkpoint inhibition • Clinical • Clinical data • Metastases • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2

HCB101 Plus Ramucirumab and Paclitaxel in Second-line Advanced Gastric Cancer: Results From a Phase 1b/2a Trial (ESMO 2026) - No abstract available

Clinical • Metastases • P1/2 data • Gastric Cancer • Oncology • Solid Tumor

Stromal caveolin-1 expression and efficacy of nab-paclitaxel + ramucirumab in unresectable gastric cancer: a multicentre retrospective study in Japan (WJOG18824G/CAPPUCCINO) (ESMO 2026) - No abstract available

Retrospective data • Stroma • Gastric Cancer • Oncology • Solid Tumor • CAV1

ALTAIR substudy 2: A Phase 1b/2 platform study evaluating rilvegostomig in combination with chemotherapy (CT), with or without ramucirumab, in patients (pts) with advanced or metastatic NSCLC (ESMO 2026) - No abstract available

Clinical • Combination therapy • Metastases • P1/2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) vs ramucirumab plus paclitaxel in second-line treatment of patients with HER2+ unresectable/metastatic gastric cancer/gastroesophageal junction adenocarcinoma from DESTINY-Gastric04 (ESMO 2026) - No abstract available

Clinical • Metastases • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2

A prospective multicenter phase II study of rechallenge treatment with ramucirumab plus erlotinib in patients with EGFR-mutated, advanced non-small cell lung cancer (NJLCG2102) (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial. (PubMed, Nat Med) - P2/3 | "In summary, evo + TRP showed encouraging efficacy with manageable safety in advanced gastric/gastroesophageal junction cancer. ClinicalTrials.gov identifier: NCT05002127 ."

Journal • P2 data • Gastric Cancer • Hematological Disorders • Oncology • Solid Tumor • CD47 • HER-2

From Cure to Recurrence: Very Early Metastatic Hepatocellular Carcinoma After Living Donor Liver Transplantation (ACG 2026) - "Sequential TKI therapy with lenvatinib and cabozantinib was limited by progression and toxicity. With AFP now >500 ng/mL, ramucirumab or regorafenib are under consideration...(B) Pankeratin (panCK) immunostain highlighting tumor cells. Original magnification Ã500."

Metastases • Cardiovascular • Fibrosis • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Oncology • Portal Hypertension • Solid Tumor • Transplantation

Anti-angiogenic therapy in thymic carcinoma: a narrative review of current evidence and emerging combinations. (PubMed, Mediastinum) - "In the first-line setting, VEGFR-2 inhibition with ramucirumab combined with platinum-based chemotherapy has achieved encouraging response rates and prolonged progression-free survival (PFS), though findings require cautious interpretation given small sample sizes and early termination of the trials without phase III confirmation. Multikinase inhibitors, such as sunitinib and lenvatinib, provide durable disease control in previously treated patients, with benefit closely linked to maintaining adequate dose intensity...The evidence base nevertheless rests on small phase II studies without confirmatory phase III data or broad regulatory approval. Future progress will depend on optimizing treatment sequencing, improving toxicity management, and advancing biomarker-driven patient selection through collaborative, multi-institutional efforts."

IO biomarker • Journal • Review • Oncology • Solid Tumor • Thymic Carcinoma • Thymic Epithelial Tumor • Thymus Cancer

TaxRamPem: Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade (clinicaltrials.gov) - P2 | N=30 | Active, not recruiting | Sponsor: Emory University | Trial primary completion date: Sep 2026 ➔ Apr 2026

Trial primary completion date • Tumor mutational burden • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-1

LIBRA: A Phase 2, Open-Label Platform Study Evaluating Novel Agent-Based Combinations in Locally Advanced or Metastatic NSCLC (IASLC-WCLC 2026) - P2 | "Approaches targeting angiogenesis and the PD-1/PD-L1 axis have demonstrated benefit in previously treated AGA-positive (the ORIENT-31 and HARMONi-A studies) and AGA-negative (the Lung-MAP S1800A study of ramucirumab [anti-VEGFR2 monoclonal antibody] plus pembrolizumab) advanced NSCLC...Dato-DXd plus ramucirumab and rilvegostomig may further improve efficacy over Dato-DXd monotherapy in patients with EGFR m NSCLC that has progressed on prior EGFR TKIs...Response and progression will be assessed by investigators per RECIST v1.1. Exploratory objectives include assessment of molecular responses based on ctDNA, pharmacodynamic and predictive biomarkers, and multiomics."

Clinical • IO biomarker • Metastases • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • TIGIT

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis. (PubMed, Cancer Treat Res Commun) - "EU/US subset analysis showed improved efficacy outcomes for RAM + ERL and a safety profile consistent with the overall population. Ramucirumab is a safe and effective addition to standard-of-care EGFR-TKI for EGFR mutation-positive metastatic NSCLC."

Clinical • Journal • Dermatitis • Dermatology • Hypertension • Immunology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma. (PubMed, JTO Clin Res Rep) - "Future research should consider exploring larger multicenter trials and other combinations to improve outcomes. Challenges in enrollment emphasize the need for innovative strategies and larger collaborations in rare malignancies such as thymic carcinoma."

Journal • Metastases • P2 data • Cardiovascular • Hematological Disorders • Neutropenia • Oncology • Solid Tumor • Thymic Carcinoma • Thymus Cancer

Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Advanced Gastric and Gastroesophageal Junction Cancer: Evidence, Sequencing, Patient Selection, and Clinical Decision-Making. (PubMed, J Gastrointest Cancer) - "T-DXd is a preferred second-line option for post-progression HER2-positive advanced gastric or gastroesophageal junction cancer, but optimal use requires careful HER2 reassessment and regionappropriate safety management. Evidence after T-DXd failure, ctDNA-guided selection, and sequential CLDN18.2-directed therapy remains limited and requires prospective validation."

Journal • Review • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Interstitial Lung Disease • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Solid Tumor • CLDN18 • HER-2

Phase 3 clinical trial of the combination of erlotinib plus ramucirumab compared with osimertinib in untreated advanced or recurrent non-small cell lung cancer with EGFR L858R mutation: The REVOL858R trial (WJOG14420L). (ASCO 2026) - "A planned E+RAM-to-OSI strategy did not improve TFS compared with upfront OSI in EGFR L858R–mutated NSCLC. Safety findings were consistent with known profiles, with higher discontinuation for tolerability in the strategy arm. Trial information: jRCTs051200142."

Clinical • Late-breaking abstract • Metastases • P3 data • Cardiovascular • Hypertension • Interstitial Lung Disease • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pulmonary Disease • Renal Disease • Respiratory Diseases • Solid Tumor • EGFR

Phase II study of the combination of durvalumab, tremelimumab, and paclitaxel as second-line chemotherapy in biomarker-selected patients with metastatic gastric cancer. (ASCO-GI 2023) - P1/2 | "Background: Currently, ramucirumab plus paclitaxel is the standard second-line chemotherapy in metastatic gastric cancer (mGC), however, its efficacy is very limited. The combination chemotherapy of durvalumab, tremelimumab, and paclitaxel showed encouraging efficacy, especially in mGC with TMB >20/Mb or MSI-high mGC, as a second-line chemotherapy with manageable toxicities in biomarker-selected mGC. Clinical trial information: NCT03751761."

Biomarker • Clinical • IO biomarker • Metastases • P2 data • Tumor mutational burden • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • PD-L1 • TMB

Biomarker analysis of pembrolizumab and ramucirumab neoadjuvant therapy for PD-L1-positive stage IB-IIIA lung cancer: EAST ENERGY trial (AACR 2024) - P2 | "In the neoadjuvant therapy with pembrolizumab and ramucirumab, immune-activated status before treatment serves as a potential biomarker for predicting treatment response. Moreover, combining ramucirumab with pembrolizumab reduced immunosuppressive cells in the TME and inhibited tumor angiogenesis. These results suggest that this combination therapy modifies the TME and augments antitumor immunity."

Biomarker • Clinical • IO biomarker • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD8 • IFNG

Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated by Gemcitabine-based Chemotherapy. (PubMed, Clin Cancer Res) - P2 | "Ramucirumab was well tolerated and resulted in PFS similar to that achieved with other chemotherapy regimens used historically for chemo-refractory BTC."

Journal • P2 data • Biliary Cancer • Biliary Tract Cancer • Cardiovascular • Cholangiocarcinoma • Gallbladder Cancer • Gastroenterology • Gastrointestinal Cancer • Gastrointestinal Disorder • Hepatology • Hypertension • Oncology • Pulmonary Embolism • Renal Disease • Respiratory Diseases • Solid Tumor

Rechallenge With Zongertinib After Trastuzumab Deruxtecan in HER2-Mutant Lung Cancer (IASLC-WCLC 2026) - "First-line combination therapy with cisplatin, pemetrexed, and pembrolizumab was initiated; however, the primary tumor progressed within 4 months. Subsequent treatments included docetaxel + ramucirumab, S1, and atezolizumab with progression-free survival (PFS) of 8, 1, and 1 months, respectively...After 7 months of Carboplatin + nab-paclitaxel treatment, owing to primary tumor enlargement, zongertinib was restarted as the eighth-line treatment...Conclusions : This report clearly demonstrates the complementary effects of the distinct mechanisms of action of zongertinib and T-DXd. Of particular interest, resistance to TKI therapy appeared reversible after intervening ADC treatment."

Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • BRAF • EGFR • FGFR3 • HER-2 • ROS1

Efficacy, Safety, and Influence on Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1 Positive NSCLC: A Phase 2 Trial (EAST ENERGY). (PubMed, Clin Cancer Res) - "This new neoadjuvant combination of pembrolizumab plus ramucirumab was feasible and anti-VEGF agents may enhance the effects of ICIs."

Biomarker • IO biomarker • Journal • P2 data • Tumor microenvironment • Giant Cell Arteritis • Immunology • Lung Cancer • Musculoskeletal Pain • Nephrology • Non Small Cell Lung Cancer • Oncology • Pain • Rheumatology • Solid Tumor • CD8 • PD-L1

Randomized phase II trial of zolbetuximab as second-line treatment in patients with claudin 18.2-positive advanced gastric/GEJ cancer with previous zolbetuximab exposure: ZELDA. (PubMed, ESMO Gastrointest Oncol) - "To investigate whether the addition of zolbetuximab to second-line nab-paclitaxel plus ramucirumab improves overall survival (OS) in patients with CLDN18.2-positive advanced gastric or GEJ adenocarcinoma who have progressed with first-line zolbetuximab-based therapy. The primary endpoint is OS in the full analysis set. Integrated translational research (ZELDA-TR) is also planned."

Journal • P2 data • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • CLDN18 • HER-2

Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671). (PubMed, Ann Oncol) - P2 | "In previously untreated advanced TC, the addition of ramucirumab to carboplatin and paclitaxel showed the highest activity compared to historical controls, with a manageable safety profile. Despite the small number of patients, given the rarity of the disease, the trial results support the consideration of this combination as first-line treatment in TC."

Journal • Metastases • P2 data • Oncology • Solid Tumor • Thymic Carcinoma • Thymus Cancer

ACCRU-GI-1810: Trifluridine/tipiracil (FTD-TPI) or paclitaxel (PAC) in combination with ramucirumab (RAM) for patients (pts) with previously treated advanced gastroesophageal adenocarcinoma (GEA)—An investigator-initiated, randomized non-inferiority phase 2 study. (ASCO-GI 2026) - P2 | "Although NI was not achieved due to early closure and small sample size, FTD-TPI+RAM was relatively safe and associated with less neuropathy compared with PAC+RAM. This regimen warrants further evaluation for pts in whom neuropathy limits taxane use."

Clinical • Combination therapy • Head-to-Head • Metastases • P2 data • Esophageal Adenocarcinoma • Esophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor